Progress and pitfalls of a year of drug repurposing screens against COVID-19

Area of Science:

• Virology
• Infectious Diseases
• Drug Discovery

Background:

• The COVID-19 pandemic, caused by a novel betacoronavirus, spurred rapid efforts to repurpose existing drugs for antiviral therapy.
• Initial drug repurposing screens faced pitfalls, including false positives from cytotoxic compounds and expedited development bypassing standard parameters, leading to suboptimal outcomes.

Purpose of the Study:

• To analyze the lessons learned from drug repurposing screens conducted during the COVID-19 pandemic.
• To critically evaluate the effectiveness of traditional drug repurposing approaches in the context of a novel viral outbreak.

Main Methods:

• Review of publications, press releases, and media reports on COVID-19 therapeutics.
• Analysis of clinical trial outcomes and emergent therapeutic strategies.
• Evaluation of the impact of urgency on drug development protocols.

Main Results:

• Many drug repurposing efforts yielded disappointing results due to methodological limitations and false positives.
• Significant clinical advancements, such as the use of immunomodulators, emerged from empirical observations rather than initial laboratory screens.
• Public confusion arose from a high volume of unverified information regarding potential treatments.

Conclusions:

• Drug repurposing for novel viral threats requires careful consideration of potential pitfalls, including compound cytotoxicity and screening biases.
• Clinical observations and empirical findings played a crucial role in identifying effective disease management strategies, complementing laboratory-based drug discovery.
• Future antiviral drug development should integrate lessons from the COVID-19 pandemic to optimize screening and clinical trial processes.